X
Feb 28, 2022 03:48 PM (GMT+8) · EqualOcean
Tonghua Dongbao announced that the SGLT1 / SGLT2 / DPP4 three target inhibitor product thdbh101 capsule developed by Dongbao Zixing (Hangzhou) biomedical Co., Ltd., a wholly-owned subsidiary, has started China's phase I clinical trial after obtaining the drug clinical trial approval of the State Drug Administration, and successfully completed the enrollment of the first subject recently.